Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

525

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Chronic Hepatitis C
Interventions
DRUG

alb-interferon alfa 2b

900 mcg every 4 weeks

DRUG

alb-interferon alfa 2b

1200 mcg every 4 weeks

DRUG

alb-interferon alfa 2b

1500 mcg every 4 weeks

DRUG

alb-interferon alfa 2b

1800 mcg every 4 weeks

DRUG

peg-interferon

Peg-interferon alfa 2a: 180 mcg 1x per wk.

Trial Locations (55)

Unknown

Novartis Investigative site, Clayton

Novartis Investigative site, Fitzroy

Novartis Investigative site, Greenslopes

Novartis Investigative site, Kingswood

Novartis Investigative site, Melbourne

Novartis Investigative site, Westmead

Novartis Investigative site, Calgary

Novartis Investigative Site, Downsview

Novartis Investigative site, Montreal

Novartis Investigative site, Toronto

Novartis Investigative site, Vancouver

Novartis Investigative Site, Cretail

Novartis Investigative Site, Nice

Novartis Investigative Site, Paris

Novartis Investigative Site, Villejuif

Novartis Investigative Site, Berlin

Novartis Investigative Site, Cologne

Novartis Investigative site, Düsseldorf

Novartis Investigative Site, Essen

Novartis Investigative Site, Freiburg im Breisgau

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Heraklion

Novartis Investigative Site, Loannina

Novartis Investigative Site, Patra-Rio

Novartis Investigative Site, Piraeurs

Novartis Investigative Site, Thessaloniki

Novartis Investigative Site, Chandigarh

Novartis Investigative site, Hyderabad

Novartis Investigative Site, Lucknow

Novartis Investigative Site, Ludhiana

Novartis Investigative Site, Mumbai

Novartis Investigative Site, New Delhi

Novartis Investigative site, Bologna

Novartis Investigative site, Milan

Novartis Investigative site, Napoli

Novartis Investigative site, Pavia

Novartis Investigative site, Pisa

Novartis Investigative site, Polermo

Novartis Investigative site, Torino

Novartis Investigative site, Bialystok

Novartis Investigative site, Lodz

Novartis Investigative site, Barcelona

Novartis Investigative site, Madrid

Novartis Investigative site, Málaga

Novartis Investigative site, Oviedo

Novartis Investigative site, Seville

Novartis Investigative site, Valencia

Novartis Investigative site, Kaohsiung City

Novartis Investigative site, Tainan City

Novartis Investigative site, Taipei

Novartis Investigative site, Bangkok

Novartis Investigative site, Chaingmai

Novartis Investigative Site, Hat Yai

Novartis Investigative Site, Muang

Novartis Investigative Site, Glasgow

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Human Genome Sciences Inc.

INDUSTRY

lead

Novartis

INDUSTRY